Note: Descriptions are shown in the official language in which they were submitted.
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-1-
STEM CELLS THAT TRANSFORM TO BEATING CARDIOMYOCYTES
PRIORITY CLAIM
This application claims priority from U.S. Application No. 10/003,400, filed
on
October 22, 2001, herein incorporated by reference.
FIELD
This application relates to the field of stem cells, specifically to methods
of
producing and differentiating muscle stem cells.
BACKGROUND
Many people die each year of congestive heart failure. Heart failure may occur
from a variety of causes, including cardiomyopathy, myocardial ischemia,
congenital heart
disease, and valvular heart disease, resulting in cardiac cell death and
myocardial
dysfunction. As cardiomyocytes are not replaced in adult myocardial tissue,
physiologic
demands on the existing, healthy, cardiomyocytes leads to their hypertrophy.
Heart
transplant has been the only recourse for patients in end-stage heart disease,
however the
United Network of Organ Sharing (UNOS) has reported that although more than
40,000
patients were waiting for heart transplants as of February 2000, only 2,345
people received a
donated heart in 1998. Furthermore, heart transplants are complicated by the
incompatibility between the transplanted donor tissue and the recipient's
immune system,
which requires life-long immunosuppression. Yet another drawback of heart
transplants is
their high cost.
An alternative approach to heart transplantation is to generate cardiomyocytes
from
stem cells in vitro that can be used in the treatment of heart failure, and
other cardiac
diseases characterized by myocardial cell death or dysfunction. This approach
is based on
the ability of stem cells to both self-renew and differentiate into one or
more mature cell
types, including cardiomyocytes. Stem cells may be obtained from an individual
suffering
from heart disease and then used to generate cardiomyocytes in vitro in order
to repair the
damaged myocardium. This approach avoids problems inherent with heart
transplantation,
such as lack of a suitable heart for transplant or immune rejection of a
transplanted heart.
Embryonic stem (ES) cells, derived from the inner cell mass of the blastocyst,
are
the most primitive stem cell, as disclosed in WO 01/11011 A2. These cells have
unlimited
self renewal capability, and because they can differentiate into several cell
lineages and
repopulate tissues upon transplantation, they have multipotent differentiative
potential.
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-2-
Although protocols are available for differentiating embryonic stem cells into
beating
cardiomyocytes, there is an ongoing ethical debate about the use of human
embryos for
medical research.
Lineage specific stem cells, identified in most organ tissues, have less self-
renewal
capability than ES cells and their differentiative ability is limited to
tissues of that lineage.
Of the lineage specific stem cells, the hematopoietic stem cell (HSC), derived
from bone
marrow, blood, cord blood, fetal liver and yolk sack, is the best
characterized. These cells
are defined by the expression of cell surface markers, such as c-kit (c-kit+),
and can
terminally differentiate into all the hematopoietic cell types. HSC have been
shown to
contribute to the formation of functional cardiac tissue in vivo (Jackson et
al. , J. Clin.
Invest., 107:1395-1402, 2001). Mesenchymal stem cells (MSC) are pluripotent
progenitor
cells derived from tissues of mesodermal origin (U.S. Patent No. 5,486,359).
These cells
are most often obtained from bone marrow, although they can be obtained from
other
sources, such as blood or dermis. These cells have been shown to differentiate
to form
muscle, bone, cartilage, fat, marrow stroma and tendon, but have not been
shown to
differentiate into cardiomyocytes. In addition, progenitor cells, termed
satellite cells
(Cornelison and Wold, Dev. Biol., 191:270-283, 1997), have been identified in
skeletal
muscle. These cells are characterized by the expression of the cell surface
marker c-met (c-
met+) in both its quiescent and activated states. When activated these cells
re-enter the cell
cycle, express myogenic regulatory factors, and differentiate into myoblasts.
However, despite the existence of a variety of stem cells, there is currently
no pure
population of stem cells that can be induced under defined conditions to
differentiate into
spontaneously beating cardiomyocytes in vitro. Thus, there remains a need in
the art for
isolated populations of stem cells that can be induced to differentiate into
cardiomyocytes.
SUMMARY
The methods and cells described herein are based on the ability of certain
stem cells
to differentiate in vitro to form fully functional cells of more than one
given type.
Disclosed herein is a novel isolated population of stem cells, called spoc
cells, that
can be induced, either in vivo or in vitro, to differentiate into
cardiomyocytes. Methods are
disclosed herein to differentiate the spoc cells, and to utilize these spoc
cells for screening
agents that affect cardiomyocytes. Methods are also provided herein to utilize
spoc cells in
therapeutic applications.
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-3-
The foregoing and other objects, features, and advantages will become more
apparent from the following detailed description of several embodiments which
proceeds
with reference to the accompanying figures.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is a series of digital images of transmission electron micrographs
demonstrating the progression of differentiation of CS (cardiac precursor from
spoc cells)
cells over time when cultured in differentiation medium. Figure lA is a
digital image of CS
cell at day 3 with disordered myosin filaments. Figure 1B is a digital image
showing that at
day 7 myosin filaments of characteristic 1.6 ~,m-length (top box) radiate
outward and the
cells contain dense bodies (lower box). Figure 1C and Figure 1F are digital
images of a cell
at day 14, showing a single, central nucleus shows a stretching out of the
dense bodies into
an organizing sarcomere. Figure 1D shows that day 3 CS cells are round cells
with copious
mitochondria (box and detail). Figure lE shows elongated day 7 cells contain
dense bodies
(arrowhead). Figure 1G shows that by day 56, a well-defined sarcomere (Figure
1G) is
present, with identifiable A- and I- bands and Z-lines.
Figure 2 demonstrates the existence of calcium transients, in cardiomyocytes
differentiated from CS cells. Figure 2A shows a graphical representation of
the calcium
transient in a beating CS cell-derived cardiomyocyte. Peak intensity and
baseline are shown
in Figure 2B and Figure 2C, respectively.
Figure 3 shows whole cell voltage recordings from spoc cell-derived
cardiomyocytes demonstrate spontaneous action potential firing in a non-
beating, teardrop
shaped cell (Figure 3A). Figure 3B shows a representative action potential
from recording
in Fig. 3A on an expanded time scale; action potential threshold is -60 mV.
Figure 3C
shows the block of action potential firing in another cell upon bath perfusion
with 0.5 mM
CdClz (horizontal bar). Acceleration of action potential firing upon perfusion
with 25 nM
isoproterenol (horizontal bar) is demonstrated in Figure 3D, indicating the
presence of
adrenergic receptors on these cells. Skeletal myotube APs differ in that their
frequency is
unaffected by Cd2+ (Figure 3E) or isoproterenol (Figure 3F).
DETAILED DESCRIPTION OF SEVERAL EMBODIMENTS
In order to facilitate review of the various embodiments disclosed herein, the
following list of abbreviations and explanation of terms is provided:
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-4-
I. Abbreviations and Terms
A. Abbreviations
CS: Cardiac precursors from spoc cells
DNA: Deoxyribonucleic acid
EGF: Epidermal growth factor
EGFP: Enhanced green fluorescent protein
ES: Embryonic stem
FAGS: Fluorescence activated cell sorting
FBS: Fetal bovine serum
FGF: Fibroblast growth factor
HSC: Hematopoietic stem cell
MI: Myocardial infarct
MRNA: Messenger ribonucleic acid
PBS: Phosphate buffered saline
RNase: Ribonuclease
RT-PCR: Reverse transcriptase-polymerase chain reaction
SP: side population
SPOC: Skeletal-based precursors of cardiomyocytes
B. Terms
Unless otherwise noted, technical terms are used according to conventional
usage.
Definitions of common terms in molecular biology may be found in Benjamin
Lewin, Genes
Vl, published by Oxford University Press, 1997 (ISBN 0-19-857778-8); Kendrew
et al.
(eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science
Ltd., 1994
(ISBN 0-632-02182-9); and Robert A. Meyers (ed.), Molecular Biology and
Biotechnology:
a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN
1
56081-569-8)
Adult: A fully developed and physically mature subject, having attained full
size
and strength.
Animal: Living mufti-cellular vertebrate organisms, a category that includes,
for
example, mammals and birds.
Cardiac: Pertaining to the heart.
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-5-
Cardiac dysfunction: Any impairment in the heart's pumping function. This
includes, for example, impairments in contractility, impairments in ability to
relax
(sometimes referred to as diastolic dysfunction), abnormal or improper
functioning of the
heart's valves, diseases of the heart muscle (sometimes referred to as
cardiomyopathy),
diseases such as angina and myocardial ischemia and infarction characterized
by inadequate
blood supply to the heart muscle, infiltrative diseases such as amyloidosis
and
hemochromatosis, global or regional hypertrophy (such as may occur in some
kinds of
cardiomyopathy or systemic hypertension), and abnormal communications between
chambers of the heart (for example, atrial septal defect). For further
discussion, see
Braunwald, Heart Disease: a Textbook of Cardiovascular Medicine, 5th edition
1997, WB
Saunders Company, Philadelphia PA (hereinafter Braunwald).
Cardiac muscle: The heart is made of specialized muscle tissue with some
similarities to both smooth and skeletal muscle. It is involuntary and most
cardiac myocytes
are mononucleate as is smooth muscle. Cardiac muscle is striated like skeletal
muscle,
which means that it has microscopically visible myofilaments arranged in
parallel including
the sarcomere. These filaments slide along each other during the process of
contraction in
the same manner as occurs in skeletal muscle. Cardiac muscle also differs from
skeletal
muscle in that the fibers in cardiac muscle branch and usually have a single
centrally located
nucleus. Another difference in cardiac muscle is the presence of intercalated
discs which
serve as specialized connections between cardiac muscle cells. These tight
connections
allow for almost completely free movement of ions so that action potentials
can freely pass
from one cell to another. This arrangement makes cardiac muscle tissue a
functional
syncytium. When one cell is excited the resultant action potential is spread
to all of them.
This is an important feature in that it allows the atrial or ventricular
muscle to contract as a
unit to forcefully pump blood. Cardiac muscle can generate its own excitatory
impulses
from the sino-atrial node, which acts like a biological pacemaker. In this
manner, the
contracting signal for cardiac muscles originates in the heart itself.
However, the autonomic
nervous system (for example through the vagus nerve) can exert control over
how fast the
signals form and propagate through the heart, which regulates the rate of
myocardial
contraction. A "cardiomyocyte" is a cell of the cardiac muscle.
Cardiac precursors from spoc cells (CS cells): When spoc cells are isolated
from
skeletal muscle and are cultured under growth conditions designed to promote
their growth,
spoc cells undergo several rounds of division. During this proliferative phase
they become
clusters of floating round cells with an increased diameter as compared to
spoc cells. These
round cells, with an increased diameter, are referred to as CS cells. In one
embodiment, a
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-6-
diameter of a CS cell is from about 10 to about 14 Vim. When placed in growth
promoting
conditions in vitro (such as the examples described below) CS cells
differentiate into
spontaneously beating cardiomyocytes.
Cardiomyopathy: Any disease or dysfunction of the myocardium (heart muscle)
in which the heart is abnormally enlarged, thickened and/or stiffened. As a
result, the heart
muscle's ability to pump blood is usually weakened. The disease or disorder
can be, for
example, inflammatory, metabolic, toxic, infiltrative, fibrotic,
hematological, genetic, or
unknown in origin. There are two general types of cardiomyopathies: ischemic
(resulting
from a lack of oxygen) and nonischemic. Ischemic cardiomyopathy is a chronic
disorder
caused by ischemia secondary to coronary artery disease - a disease in which
there is
atherosclerotic narrowing or occlusion of the coronary arteries on the surface
of the heart.
Coronary artery disease often leads to episodes of cardiac ischemia, in which
the heart
muscle is not supplied with enough oxygen-rich blood. Eventually, the heart
muscle is
weakened because of areas that no longer function due to myocyte death from
ischemia.
Larger volumes of blood are needed to fill the heart to augment output from
the failing
heart. This eventually leads to dilatation and worsening cardiac function.
Nonischemic cardiomyopathy is generally classified into three groups based
primarily on clinical and pathological characteristics:
(1) dilated cardiomyopathy, a syndrome characterized by cardiac enlargement
and
impaired systolic function of one or both ventricles;
(2) hypertrophic cardiomyopathy, herein defined as (a) global or regional
increase in thickness of either ventricular wall or the interventricular
septum, or
(b) an increased susceptibility to global or regional increase in thickness of
either ventricular wall or the interventricular septum, such as can occur in
genetic diseases, hypertension, or heart valve dysfunction; or
(3) restrictive and infiltrative cardiomyopathies, a group of diseases in
which the
predominant clinical feature is usually impaired ability of the heart to relax
(diastolic dysfunction), and is often characterized by infiltration of the
heart
muscle with foreign substances such as amyloid fibers, iron, or glycolipids.
See Wynne and Braunwald, The Cardiomyopathies and Myocarditities, Chapter 41,
supra.
CD34: A cell surface antigen formerly known as hematopoietic progenitor cell
antigen 1, and MY10, is a known marker of human hematopoietic stem cells. The
human
CD34 gene, which maps to chromosome 1q32, spans 26 kb and has 8 exons. CD34 is
a 67
kDa transmembrane glycoprotein. CD34 is expressed selectively on human
hematopoietic
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
progenitor cells and such a cell is CD34 positive (CD34+). A cell that does
not express
CD34 is CD34 negative (CD34-). The biological function of CD34 is still
unknown.
Cell surface marker: A protein, glycoprotein, or other molecule expressed on
the
surface of a cell, which serves to help identify the cell. A cell surface
marker can generally
be detected by conventional methods. Specific, non-limiting examples of
methods for
detection of a cell surface marker are immunohistochemistry, fluorescence
activated cell
sorting (FACS), or an enzymatic analysis.
c-kit: A proto-oncogene that encodes a transmembrane receptor with intrinsic
tyrosine-specific protein kinase activity in its intracellular domain. It is
the cellular
homologue of the viral kit oncogene of HZ4-FSV (Hardy-Zuckerman 4 feline
sarcoma
virus). The kit receptor is also known as CD117. The ligand for the kit
receptor is Stem
Cell Factor.
Human c-kit maps to chromosome 4q11-q12 in the same region also encoding one
of the platelet derived growth factor (PDGF) receptors (PDGFRA). The two genes
have
been located on a DNA fragment of approximately 700 kb. The human kit gene has
a length
of more than 70 kb and contains 21 exons. The longest transcript is 5230 by
and is
alternatively spliced. A c-kit negative (c-kit ) cell is a cell that does not
express c-kit. A cell
that expresses c-kit is c-kit positive (c-kit+).
c-met: A proto-oncogene that encodes a transmembrane receptor tyrosine kinase
that transduces mitogenic, migratory, or morphogenic signals in a variety of
non-muscle
tissues during development and wound healing in response to its ligand
hepatocyte growth
factor (HGF)/scatter factor. HGF is a plasminogen-like protein thought to be a
humoral
mediator of liver regeneration. In muscle development HGF/c-met signaling is
essential for
proper emigration of muscle precursor cells of the axial lineage during
embryogensis. The
c-met gene product is synthesized as a 190kDa precursor and is proteolytically
processed
into an amino terminal 50 KDa alpha chain and a carboxy terminal 140KDa beta
chain.
c-met is expressed in quiescent satellite cells but not in muscle-derived
fibroblasts
or other mononucleated cells from healthy muscle explants (Cornelison and
Wold,
Developmental Biology, 191:270, 1997). Met plays a role in normal
hematopoiesis, and is
expressed in various lymphoid and leukemic cell lines. It also contributed to
the malignant
progression of gliomas. A c-met negative
(c-met ) cell is a cell that does not express c-met. A cell that expresses c-
met is c-met
positive (c-met+).
Congenital heart disease: A heart-related problem that is present since birth
and
often as the heart is forming even before birth. Congenital heart disease may
affect the
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
_g_
heart, the heart's valves, the veins leading to, or the arteries leading away,
from the heart, or
the connections between these parts of the body.
Differentiation: The process whereby relatively unspecialized cells (e.g.,
stem
cells) acquire specialized structural and/or functional features
characteristic of mature cells.
Similarly, "differentiate" refers to this process. Typically, during
differentiation, cellular
structure alters and tissue-specific proteins appear. The term "differentiated
muscle cell"
refers to cells expressing proteins characteristic of the specific muscle cell
type. A
differentiated muscle cell includes a skeletal muscle cell, a smooth muscle
cell, and a
cardiac muscle cell.
Differentiation Medium: A synthetic set of culture conditions with the
nutrients
necessary to support the growth or survival of cultured cells, and which
allows the
differentiation of stem cells into differentiated cells.
DNA: Deoxyribonucleic acid. DNA is a long chain polymer which comprises the
genetic material of most living organisms (some viruses have genes comprising
ribonucleic
acid (RNA)). The repeating units in DNA polymers are four different
nucleotides, each of
which comprises one of the four bases, adenine, guanine, cytosine and thymine
bound to a
deoxyribose sugar to which a phosphate group is attached. Triplets of
nucleotides (referred
to as codons) code for each amino acid in a polypeptide. The term codon is
also used for the
corresponding (and complementary) sequences of three nucleotides in the mRNA
into
which the DNA sequence is transcribed.
Epidermal growth factor (EGF): In particular examples, EGF is a globular
protein of 6.4 kDa consisting of 53 amino acids. It contains three
intramolecular disulfide
bonds essential for biological activity. EGF proteins are evolutionarily
closely conserved.
Human EGF and murine EGF have 37 amino acids in common. Approximately 70
percent
homology is found between human EGF and EGF isolated from other species.
Mammalian
EGF includes, but is not limited to, murine, avian, canine, bovine, porcine,
equine, and
human EGF. The amino acid sequences and methods for making these EGF
polypeptides
are well known in the art.
The gene encoding the EGF precursor has a length of approximately 110 kb, and
contains 24 exons. Fifteen of these exons encode protein domains that are
homologous to
domains found in other proteins. The human EGF gene maps to chromosome 4q25-
q27.
EGF is a strong mitogen for many cells of ectodermal, mesodermal, and
endodermal
origin. EGF controls and stimulates the proliferation of epidermal and
epithelial cells,
including fibroblasts, kidney epithelial cells, human glial cells, ovary
granulosa cells, and
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-9-
thyroid cells in vitro. EGF also stimulates the proliferation of embryonic
cells. However,
the proliferation of some cell lines has been shown to be inhibited by EGF.
EGF is also known to act as a differentiation factor for some cell types. It
strongly
influences the synthesis and turn-over of proteins of the extra-cellular
matrix including
fibronectin, collagen, laminin, and glycosaminoglycans, and has been shown to
be a strong
chemoattractant for fibroblasts and epithelial cells.
EGF can be assayed in a cell-based assay wherein the proliferation of a cell
population is assessed. EGF can also be assayed by an immunoassay, such as an
ELISA
assay.
Fragments of EGF, smaller than the full-length sequence can also be employed
in
methods disclosed herein. Suitable biologically active variants can also be
utilized. One
specific, non-limiting example of an EGF variant of use is an EGF sequence
having one or
more amino acid substitutions, insertions, or deletions, wherein a biological
function of EGF
is retained. Another specific, non-limiting example of an EGF variant is EGF
as wherein
glycosylation or phosphorylation is altered, or a foreign moiety is added, so
long as a
biological function of EGF is retained. Methods for making EGF fragments,
analogues, and
derivatives are available in the art. Examples of EGF variants are known in
the art, for
example U.S. Patent No. 5,218,093 and WO 92/16626A1. Examples of EGF from many
different species are disclosed in WO 92/16626A1, as are examples of variants,
and
strategies for producing them.
As used herein, "EGF" refers to naturally occurnng EGF, and variants and
fragments that perform the same function of EGF in the culture media disclosed
herein.
Embryonic stem (ES) cells: Totipotent cells isolated from the inner cell mass
of
the developing blastocyst and can generate all of the cells present in the
body (for example,
bone, muscle, brain cells, etc.). "ES cells" can be derived from any organism,
for example
from mammals such as humans.
Fibroblast growth factor (FGF): Any suitable fibroblast growth factor, derived
from any animal, and functional variants and fragments thereof. A variety of
FGFs are
known and include, but are not limited to, FGF-1 (acidic fibroblast growth
factor), FGF-2
(basic fibroblast growth factor, bFGF), FGF-3 (int-2), FGF-4 (hst/K-FGF), FGF-
5, FGF-6,
FGF-7, FGF-8, and FGF-9. FGF refers to a fibroblast growth factor protein such
as FGF-1,
FGF-2, FGF-4, FGF-6, FGF-8, or FGF-9, or a biologically active fragment or
mutant
thereof. The FGF can be from any animal species. In one embodiment the FGF is
mammalian FGF including but not limited to, rodent, avian, canine, bovine,
porcine, equine,
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
- 10-
and human. The amino acid sequences and method for making many of the FGFs are
well
known in the art.
Fragments of FGF that are smaller than those described can also be employed.
Suitable biologically active variants can be FGF analogues or derivatives. An
analogue of
S FGF is either FGF or an FGF fragment that includes a native FGF sequence and
structure
having one or more amino acid substitutions, insertions, or deletions. Analogs
having one
or more peptoid sequences (peptide mimic sequences) are also included (see
e.g.
International Publication No. WO 91/04282). By "derivative" is intended any
suitable
modification of FGF, FGF fragments, or their respective analogues, such as
glycosylation,
phosphorylation, or other addition of foreign moieties, so long as the FGF
activity is
retained. Methods for making FGF fragments, analogues, and derivatives are
available in
the art.
Growth factor: A substance that promotes cell growth, survival, and/or
differentiation. In general, growth factors stimulate cell proliferation or
maturation when
they bind to their receptor. In one embodiment, growth factors are a complex
family of
polypeptide hormones or biological factors that control growth, division, and
maturation of
muscle cells. In another embodiment a growth factor can be used to promote the
proliferation of muscle stem cells and maintain the stem cells in an
undifferentiated state. A
growth factor can be a naturally occurring factor or a factor synthesized
using molecular
biology techniques. Examples of growth factors include platelet-derived growth
factor,
fibroblast growth factor, epidermal growth factor, insulin, somatomedin, stem
cell factor,
vascular endothelial growth factor, granulocyte colony stimulating factor, and
transforming
growth factor-beta, amongst others. A muscle cell growth factor is a growth
factor that
effects the development (maturation), differentiation, division, or
proliferation of muscle
cells.
Growth medium: A synthetic set of culture conditions with the nutrients
necessary
to support the growth or survival of microorganisms or culture cells.
Heart: The muscular organ of an animal that circulates blood. The walls of the
heart are comprised of working muscle, or myocardium, and connective tissue.
Myocardium is comprised of myocardial cells, which are also referred to herein
as cardiac
cells, cardiac myocytes, cardiomyocytes and/or cardiac fibers. Cardiomyocytes
may be
cells of the atrium or cells of the ventricle.
Heart failure: The inability of the heart to supply sufficient oxygenated
blood to
meet the metabolic needs of the tissues and cells in a subject. This can be
accompanied by
circulatory congestion, such as congestion in the pulmonary or systemic veins.
As used
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-11-
herein, the term heart failure encompasses heart failure from any cause, and
is intended
herein to encompass terms such as "congestive heart failure," "forward heart
failure,"
"backward heart failure," "high output heart failure," "low output heart
failure," and the
like. See Chapters 13-17 in Braunwald for a detailed discussion. Conditions
that could lead
to heart failure include, but are not limited to, coronary artery disease,
cardiomyopathy, or
congenital heart disease.
Heterologous: A heterologous sequence is a sequence that is not normally (i.e.
in
the wild-type sequence) found adjacent to a second sequence. In one
embodiment, the
sequence is from a different genetic source, such as a virus or organism, than
the second
sequence.
Isolated: An "isolated" biological component (such as a nucleic acid molecule,
protein or organelle) has been substantially separated or purified away from
other biological
components in the cell of the organism in which the component naturally
occurs, i.e., other
chromosomal and extra-chromosomal DNA and RNA, proteins and organelles.
Nucleic
acids and proteins that have been "isolated" include nucleic acids and
proteins purified by
standard purification methods. The term also embraces nucleic acids and
proteins prepared
by recombinant expression in a host cell as well as chemically synthesized
nucleic acids.
Lineage specific marker: A marker that is expressed by a specific population
of
cells. In one embodiment, the cells are cells of a muscle, other than
satellite cells, such as
spoc cells.
Mammal: This term includes both human and non-human mammals. Similarly,
the term "subject" includes both human and veterinary subjects.
Muscle cell: Includes skeletal, cardiac or smooth muscle tissue cells. This
term is
synonymous with myocyte, and encompasses those cells which differentiate to
form more
specialized muscle cells (e.g. myoblasts). "Cardiomyocyte" refers to a cardiac
muscle cell.
Myocardial injury: Damage to the muscle or the "myocardium" in the wall of the
heart as a result of disease or trauma. Myocardial injury can be attributed to
many things
such as, but not limited to, cardiomyopathy, myocardial infarction, or
congenital heart
disease.
Nucleotide: "Nucleotide" includes, but is not limited to, a monomer that
includes a
base linked to a sugar, such as a pyrimidine, purine or synthetic analogs
thereof, or a base
linked to an amino acid, as in a peptide nucleic acid (PNA). A nucleotide is
one monomer
in a polynucleotide. A nucleotide sequence refers to the sequence of bases in
a
polynucleotide.
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-12-
Operably linked: A first nucleic acid sequence is operably linked with a
second
nucleic acid sequence when the first nucleic acid sequence is placed in a
functional
relationship with the second nucleic acid sequence. For instance, a promoter
is operably
linked to a coding sequence if the promoter affects the transcription or
expression of the
coding sequence. Generally, operably linked DNA sequences are contiguous and,
where
necessary to join two protein coding regions, in the same reading frame.
Pax: A member of a family of evolutionary conserved transcription factors,
termed
"paired box transcription factors" There are nine members of this family, each
of which
contain a conserved DNA binding domain of 128 amino acids, known as the paired
domain.
The Pax gene family of nuclear transcription factors function during
embryogenesis
to regulate the temporal and position-dependent differentiation of cells. In
addition, the
family is involved in a variety of signal transduction pathways in the adult
organism. For
example, Pax3 transcription factor is thought to specify dorsal cell fate in
the neural tube.
Pax7 is expressed within the muscle satellite cell lineage, and skeletal
muscle from Pax7-~-
mice is completely ablated of satellite cells. Mutations in the Pax family of
proteins have
been linked to disease and cancer in humans. For example, several Pax genes
have been
identified as targets of specific tumor associated chromosomal translocations.
A cell that is Pax(3/7)- does not express Pax3 or Pax7, as detected by a
Pax(3/7)
antibody. This antibody is reactive with both Pax-3 and Pax-7 but does not
cross-react with
other members of the Pax transcription factor family. A cell that is
Pax(3/7)+, as detected by
the Pax(3/7) antibody, expresses either Pax3, or Pax7, or both Pax3 and Pax7.
Pharmaceutically acceptable carriers: Remington's Pharmaceutical Sciences, by
E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes
compositions and formulations suitable for pharmaceutical delivery of stem
cells herein
disclosed.
In general, the nature of the carrier will depend on the particular mode of
administration being employed. For instance, parenteral formulations usually
comprise
injectable fluids that include pharmaceutically and physiologically acceptable
fluids such as
water, physiological saline, balanced salt solutions, aqueous dextrose,
glycerol or the like as
a vehicle. In addition to biologically-neutral carriers, pharmaceutical
compositions to be
administered can contain minor amounts of non-toxic auxiliary substances, such
as wetting
or emulsifying agents, preservatives, and pH buffering agents and the like,
for example
sodium acetate or sorbitan monolaurate.
Pharmaceutical agent: A chemical compound or composition capable of inducing
a desired therapeutic or prophylactic effect when properly administered to a
subject or a
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-13-
cell. "Incubating" includes exposing a target to an agent for a sufficient
period of time for
the agent to interact with a cell. "Contacting" includes incubating an agent
in solid or in
liquid form with a cell.
Polypeptide A polymer in which the monomers are amino acid residues which are
joined together through amide bonds. When the amino acids are alpha-amino
acids, either
the L-optical isomer or the D-optical isomer can be used, the L-isomers being
preferred.
The terms "polypeptide" or "protein" as used herein is intended to encompass
any amino
acid sequence and include modified sequences such as glycoproteins. The term
"polypeptide" is specifically intended to cover naturally occurnng proteins,
as well as those
which are recombinantly or synthetically produced.
The term "polypeptide fragment" refers to a portion of a polypeptide which
exhibits
at least one useful epitope. The term "functional fragments of a polypeptide"
refers to all
fragments of a polypeptide that retain an activity of the polypeptide.
Biologically functional
fragments, for example, can vary in size from a polypeptide fragment as small
as an epitope
capable of binding an antibody molecule to a large polypeptide capable of
participating in
the characteristic induction or programming of phenotypic changes within a
cell. An
"epitope" is a region of a polypeptide capable of binding an immunoglobulin
generated in
response to contact with an antigen. Thus, smaller peptides containing the
biological
activity of insulin, or conservative variants of the insulin, are thus
included as being of use.
The term "soluble" refers to a form of a polypeptide that is not inserted into
a cell
membrane.
The term "substantially purified polypeptide" as used herein refers to a
polypeptide
which is substantially free of other proteins, lipids, carbohydrates or other
materials with
which it is naturally associated. In one embodiment, the polypeptide is at
least 50%, for
example at least 80% free of other proteins, lipids, carbohydrates or other
materials with
which it is naturally associated. In another embodiment, the polypeptide is at
least 90% free
of other proteins, lipids, carbohydrates or other materials with which it is
naturally
associated. In yet another embodiment, the polypeptide is at least 95% free of
other
proteins, lipids, carbohydrates or other materials with which it is naturally
associated.
Conservative substitutions replace one amino acid with another amino acid that
is
similar in size, hydrophobicity, etc. Examples of conservative substitutions
are shown
below.
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-14-
Original Residue Conservative Substitutions
Ala Ser
Arg Lys
Asn Gln, His
Asp Glu
Cys Ser
Gln Asn
Glu Asp
His Asn; Gln
Ile Leu, Val
Leu Ile; Val
Lys Arg; Gln; Glu
Met Leu; Ile
Phe Met; Leu; Tyr
Ser Thr
Thr Ser
Trp Tyr
Tyr Trp; Phe
Val Ile; Leu
Variations in the cDNA sequence that result in amino acid changes, whether
conservative or not, are usually minimized in order to preserve the functional
and
immunologic identity of the encoded protein. The immunologic identity of the
protein may
be assessed by determining whether it is recognized by an antibody; a variant
that is
recognized by such an antibody is immunologically conserved. Any cDNA sequence
variant will preferably introduce no more than twenty, and preferably fewer
than ten amino
acid substitutions into the encoded polypeptide. Variant amino acid sequences
may, for
example, be 80, 90 or even 95% or 98% identical to the native amino acid
sequence.
Programs and algorithms for determining percentage identity can be found at
the NCBI
website.
Precursor Cell: A cell that can generate a fully differentiated functional
cell of at
least one given cell type. Generally, precursor cells can divide. After
division, a precursor
cell can remain a precursor cell, or may proceed to terminal differentiation.
A "muscle
precursor cell" is a precursor cell that can generate a fully differentiated
functional muscle
cell, such as a cardiomyocyte or a skeletal muscle cell. One specific, non-
limiting example
of a muscle precursor cell is a "cardiomyocyte precursor cell," which is a
cell that gives rise
to cardiac muscle cells.
Progenitor Cell: A cell that gives rise to progeny in a defined cell lineage.
A
"muscle progenitor cell" is a cell that gives rise to cells of the muscle
lineage. One specific,
non-limiting, example of a skeletal muscle progenitor cell is a "satellite
cell," which gives
rise to immature and mature skeletal muscle cells.
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-15-
Recombinant: A recombinant nucleic acid is one that has a sequence that is not
naturally occurring or has a sequence that is made by an artificial
combination of two
otherwise separated segments of sequence. This artificial combination is often
accomplished by chemical synthesis or, more commonly, by the artificial
manipulation of
isolated segments of nucleic acids, e.g., by genetic engineering techniques.
Similarly, a
recombinant protein is one encoded for by a recombinant nucleic acid molecule.
Side population (SP) cells: A collection of cells that does not express the
same
complement of markers as the cells of interest. In one specific non-limiting
example, a side
population includes cells that express Sca-1. In another non-limiting example,
the side
population cells are c-kit c-met CD34-Pax(3/7)-Sca-1+.
Skeletal muscle: Skeletal muscle makes up most of the body's muscle and does
not
contract without nervous stimulation. It is under voluntary control and lacks
anatomic
cellular connections between fibers. The fibers (cells) are multinucleate and
appear striated
due to the arrangement of actin and myosin protein filaments. Each fiber is a
single cell,
long, cylindric and surrounded by a cell membrane. The muscle fibers contain
many
myofibrils that are made of myofilaments. These myofilaments are made up of
contractile
proteins. The key proteins in muscle contraction are myosin, actin,
tropomyosin and
troponin.
Skeletal-based precursor of cardiomyocytes (Spoc) cells: Stem cells derived
from skeletal muscle, which do not express the cell surface markers c-met, c-
kit, or CD34,
that can be differentiated into cardiomyocytes. Spoc cells can be further
purified by sorting
for the Sca-1 cell surface marker (found on hematopoietic cells). Spoc cells
are thus Sca-1-,
distinguishing them from side population (SP) cells. In addition, spoc cells
do not express
the Pax3 and Pax 7 transcription factors (Pax(3/7)). Thus, in one non-limiting
example,
spoc cells are c-kit c-met-CD34~Sca-1-Pax(3/7)-. In another non-limiting
example spoc cells
are muscle derived precursor cells that are about 4 pm in diameter when
cultured in vitro.
These cells remain in suspension and proliferate when cultured in the presence
of a growth
factor. Specific, non-limiting examples of growth factors of use in
propagating spoc cell are
FGF, EGF, or a combination thereof.
In one embodiment, spoc cells can differentiate into spontaneously beating
cardiomyocytes in vitro. During a proliferative phase (e.g. about 7 days after
being
maintained in vitro in the presence of a growth factor), spoc cells cluster
and increase in size
to about 10-14 pm in diameter. The cells in these clusters, referred to as CS
cells, have the
ability to differentiate into mature cardiac muscle cells when cultured in the
absence of
growth factors. Methods for isolating and differentiating spoc cells are
disclosed herein.
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-16-
Spontaneous: Arising from an internal cause, resulting from internal or
natural
processes, with no apparent external influence. A "spontaneously beating
cardiomyocyte"
is a cell that begins to beat as a result of internal signals.
Stem cell: A cell that can generate a fully differentiated functional cell of
more
than one given cell type. The role of stem cells in vivo is to replace cells
that are destroyed
during the normal life of an animal. Generally, stem cells can divide without
limit. After
division, the stem cell may remain as a stem cell, become a precursor cell, or
proceed to
terminal differentiation. Although appearing morphologically unspecialized,
the stem cell
may be considered differentiated where the possibilities for further
differentiation are
limited. A "muscle stem cell" is a stem cell derived from muscle or that gives
rise to muscle
cells after differentiation. One specific, non-limiting example of a muscle
stem cell is a cell
that gives rise to cardiac muscle cells.
Stem cell antigen-1 (Sca-1): A murine cell surface antigen also called also Ly-
6A/E. Sca-1 is expressed on immature hematopoietic progenitor cells and stem
cells.
Antibodies directed against Sca-1 have been used to fractionate early
hematopoietic
progenitor cells that have the ability to repopulate bone marrow in vivo. A
cell that does not
express Sca-1 is Sca-1 negative (Sca-I-), whereas a cell that expresses Sca-1
is Sca-1
positive (Sca-1+). In specific, non-limiting examples, expression of Sca-I (or
any other cell
marker) can be measured by fluorescence activated cell sorting (FACS) or
immunohistochemistry.
Subject: Any mammal, such as humans, non-human primates, pigs, sheep, cows,
rodents and the like which is to be the recipient of the particular treatment.
In one
embodiment, a subject is a human subject or a murine subject.
Suspension: A dispersion of solid particles, such as a cell, throughout the
body of a
liquid, such as a culture medium or an isotonic (physiologically compatible)
buffer.
Therapeutic agent: Used in a generic sense, it includes treating agents,
prophylactic
agents, and replacement agents.
Therapeutically effective amount: The amount of agent that is sufficient to
prevent, treat, reduce and/or ameliorate the symptoms and/or underlying causes
of any of a
disorder or disease. In one embodiment, a "therapeutically effective amount"
is sufficient to
reduce or eliminate a symptom of a cardiac disease. In another embodiment, a
therapeutically effective amount is an amount sufficient to overcome the
disease itself.
A therapeutically effective amount of an agent can be administered in a single
dose,
or in several doses, for example daily, during a course of treatment. However,
the effective
amount of the agent will be dependent on the subject being treated, the
severity and type of
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-17-
the condition, and the manner of administration of the compound.
"Administering" can be
accomplished by introducing the therapeutically effective amount locally or
systemically
into the subject. Systemic introduction can be accomplished by using an
intravenous,
intramuscular, transcutaneous or subcutaneous means. Such means could include
introducing the therapeutically effective amount via injection, or via
catheter.
The general term "administering a therapeutically effective amount to the
subject"
is understood to include all animals (e.g. humans, apes, dogs, cats, horses,
and cows) that
have or may develop some form of cardiac dysfunction.
Therapeutically effective amount of a cell: An amount of a spoc cell (e.g. a c-
kit
c-met CD34-Sca-1-Pax(3/7)- cell) that can be determined by various methods,
including
generating an empirical dose-response curve, predicting potency and efficacy
of using
modeling, and other methods used in the biological sciences. In general, a
therapeutically
effective amount of a c-kit c-met CD34-Sca-1-Pax(3/7)- cell is an amount
sufficient to
prevent, treat, reduce, eliminate and/or ameliorate a symptom and/or the
underlying causes
of a cardiac disease. In one embodiment, a therapeutically effective amount is
an amount
sufficient to overcome a cardiac disorder.
The therapeutically effective amount of c-kit c-met CD34-Sca-1-Pax(3/7)-cells
will
be dependent on the subject being treated (e.g. the species or size of the
subject), the type of
cardiac dysfunction suffered by the subject, and the location of
administration of the cells
(e.g. intravenously, locally, etc). In one embodiment, a therapeutically
effective amount of
cells is an amount of cells sufficient to treat a subject suffering from a
myocardial injury. In
specific, non-limiting examples, a therapeutically effective amount of c-kit c-
met CD34-
Sca-1-Pax(3/7)-cells is more than about 100 cells, more than about 1000 cells,
more than
about 10,000 cells, more than about 100,000 cells, more than about 250,000
cells, more
than about 1,000,000 cells, or between about 250,000 cells and about 1,000,000
cells.
Specific assays for determining the therapeutically effective amount of c-kit
c-met
CD34-Sca-1-Pax(3/7)- cells are provided herein. The methods disclosed in the
present
invention have equal application in medical and veterinary settings.
Therefore, the general
term "subject being treated" is understood to include all animals (e.g.
humans, apes, dogs,
cats, mice, rats, rabbits, sheep, pigs, mice and cows) and treatment of
myocardial injury is
monitored using assays that measure cardiac function. Other assays can
determine the
success of engraftment of c-kit c-met CD34~Sca-1-Pax(3/7)- cardiomyocyte
precursor cells
following transplantation.
Transfected: A transfected cell is a cell into which has been introduced a
nucleic
acid molecule by molecular biology techniques. As used herein, the term
transduction
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-18-
encompasses all techniques by which a nucleic acid molecule might be
introduced into such
a cell, including transduction with viral vectors, transformation with plasmid
vectors, and
introduction of DNA by electroporation, lipofection, and particle gun
acceleration.
Transplantation: The transfer of a tissue or an organ, or a portion thereof,
from
one body or part of the body to another body or part of the body.
Vector: A nucleic acid molecule as introduced into a host cell, thereby
producing a
transformed host cell. Recombinant DNA vectors are vectors having recombinant
DNA. A
vector can include nucleic acid sequences that permit it to replicate in a
host cell, such as an
origin of replication. A vector can also include one or more selectable marker
genes and
other genetic elements known in the art. Viral vectors are recombinant DNA
vectors having
at least some nucleic acid sequences derived from one or more viruses.
Unless otherwise defined, all technical and scientific terms used herein have
the
same meaning as commonly understood by one of ordinary skill in the art.
Although
methods and materials similar or equivalent to those described herein can be
used, suitable
methods and materials are described below. In case of conflict, the present
specification,
including the explanation of terms, will control. In addition, the materials,
methods, and
examples are illustrative only and not intended to be limiting.
Spoc Cells
Stem cells derived from skeletal muscle (spoc cells) are disclosed herein.
Spoc cells
do not express the cell surface markers c-met, CD34, Sca-1, or c-kit. In
addition, spoc cells
do not express the Pax3 and Pax7 transcription factors. Thus, in one example,
spoc cells are
termed c-met c-kit CD34-Sca-1-Pax(3/7)~. Spoc cells can be isolated from any
age mammal,
either human or non-human. Thus spoc cells can be obtained from a fetus, a
child or an
adult of any mammalian species. In one embodiment, a spoc cell is a human or
murine c-
met c-kit CD34-Sca-1-Pax(3/7)- cell that can be differentiated into a
cardiomyocyte in vitro.
In one embodiment, the spoc cell is between about 3~m and lOpm in diameter, or
are about
4 p,m in diameter.
Culture conditions for spoc cells (e.g. c-kit c-met CD34-Sca-1-Pax(3/7)-
cells) have
been identified and are disclosed herein. In one embodiment, spoc cells do not
adhere to the
culture dish but remain in suspension when cultured in the presence of at
least one growth
factor. In one specific, non-limiting example, the growth factor is EGF. In
another specific,
non-limiting example, the growth factor is FGF.
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-19-
Culture conditions are also disclosed herein (see below) for differentiating
spot
cells. The differentiation of spot cells into cardiomyocytes can be assessed
by observing
morphological changes. In some examples, differentiated spot cells are
spontaneously
beating cardiomyocytes. In several embodiments, organized gap junctions and
sarcomeres
with clear Z- lines and A- and I-bands, are observed in the differentiated
spot cells. In
addition, certain examples of the differentiated spot cells may be mono- or
mufti-nucleate.
In one specific, non-limiting example, the cells are bi-nucleate.
The isolated spot cell (e.g. a c-kit c-met CD34-Sca-1-Pax(3/7)~ cell) can be
transduced using standard procedures known in molecular biology in order to
introduce a
nucleic acid molecule of interest into the cell. In one embodiment, the
nucleic acid
molecule encodes a polypeptide. The polypeptide encoded by the nucleic acid
molecule can
be from the same species as the cells (homologous), or can be from a different
species
(heterologous). For example, a nucleic acid molecule can be utilized that
supplements or
replaces deficient production of a peptide by the tissue of the host wherein
such deficiency
i.s a cause of the symptoms of a particular disorder. In this case, the cells
act as a source of
the peptide. In one specific, non-limiting example the polypeptide is the
cardiac specific
transcription factor GATA-4.
In one embodiment, the nucleic acid molecule of interest encodes a polypeptide
involved in growth regulation or neoplastic transformation of cardiac cells.
Specific, non-
limiting examples of nucleic acids sequences of interest are SV40 Tag, p53,
myc, src, and
bcl-2. In another embodiment, the nucleic acid sequence of interest encodes an
enzyme.
Specific, non-limiting examples of enzymes are proteins involved in the
conversion of a
pro-drug to a drug, or growth factors that promote the expansion,
differentiation, or survival
of cardiac progenitor cells, such as EGF, FGF, or atrial natriuretic factor.
In yet another
embodiment, the nucleic acid sequence of interest encodes a transcriptional
regulator.
In one embodiment, the nucleic acid sequence of interest is operably linked to
a
regulatory element, such as a transcriptional and/or translational regulatory
element.
Regulatory elements include elements such as a promoter, an initiation codon,
a stop codon,
mRNA stability regulatory elements, and a polyadenylation signal. A promoter
can be a
constitutive promoter or an inducible promoter. Specific non-limiting examples
of
promoters include the CMV promoter, an atrial natriuretic factor promoter, and
promoters
including TET-responsive element for inducible expression of transgene. In
another
embodiment, the nucleic acid sequence of interest is inserted into a vector,
such as an
expression vector. Procedures for preparing expression vectors are known to
those of skill
in the art and can be found in Sambrook et al., Molecular Cloning: A
Laboratory Manual,
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-20-
2nd Ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989). Expression
of the
nucleic acid of interest occurs when the expression vector is introduced into
an appropriate
host cell.
In yet another specific, non-limiting example, a nucleic acid sequence can be
introduced to decrease rejection. For example, the immunogenicity of a cell
may be
suppressed by deleting genes that produce proteins that are recognized as
"foreign" by the
host (a knock-out), or by introducing genes which produce proteins, such as
proteins that
are native to the host and recognized as "self' proteins by the host immune
system.
Thus in one embodiment, a spoc cell (e.g. a c-kit c-met CD34-Sca-1-Pax(3/7)-
cell)
may be transfected with a nucleic acid molecule designed to functionally
delete or "knock-
out" a gene of interest. In this method, the nucleic acid molecule of interest
is a nucleic
acid molecule that undergoes homologous recombination and is inserted into the
genome of
the spoc cell. Methods for producing "knock-outs" in ES cells are known to one
of skill in
the art (e.g. see U.S. Patent No. 5,939,598; W000214495A2).
According to this example, cells are_cultured in vitro as described herein and
an exogenous
nucleic acid is introduced into the cells by any method known to one of skill
in the art, for example,
by transfection or electroporation. The transfected cultured cells can then be
studied in vitro or can
be administered to a subject (see below). Methods for the introduction of
nucleic acid sequences into
stem cells are known in the art (e.g., see U.S. Patent No. 6,110,743).
Methods of Isolating and Expanding Muscle Stem Cells
A method of isolating a spoc cell (e.g. a c-met c-kit CD34-Sca-1-Pax(3/7)-
cardiomyocyte precursor cell of muscular origin) is described herein. In this
method, spoc
cells are separated by size from a suspension of muscle cells and the cells
are cultured on a
solid substrate. The cells that remain in suspension in the culture medium are
isolated.
The method of isolation of the spoc cells (e.g. c-kit c-met CD34-Sca-1-
Pax(3/7)-
cells) includes obtaining the cells from the muscle of a subject. Muscle
tissue can be
prepared for the purpose of isolating or obtaining individual spoc cells by
using methods
well known to one of skill in the art. Examples of methods of tissue
preparation include
enzymatic digestion with enzymes such as collagenase, mechanical disruption
using
instruments such as hand-held or motor-driven homogenizers, or by chemical
disruption
using, for example, chelators of calcium and magnesium.
The preparation of muscle cells can be sorted by any method that separates
cells on
the basis of cell size. In one embodiment, the spoc cells (e.g. c-kit c-met
CD34-Sca-1~
Pax(3/7)~ cells) are isolated by passing digested skeletal muscle through a
series of filters of
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-21-
varying pore size. The muscle cells are passed through two filters, where a
first filter has a
pore size of about 50-200 Vim, about 60-150 Vim, about 80-100 pm, or about 100
~m and a
second filter has a pore size of about 10-50 Vim, 20-40 pm, or about 40 ~.m.
In one
embodiment the isolated cells are less than 40 ~,m in diameter. In other
embodiments,
isolated cells are between about 3 ~m and 10 ~m in diameter. In another
embodiment the
isolated cells are about 4 ~m in diameter.
The muscle cells can be also sorted by size by passing them through size-
exclusion
columns. In one such embodiment, the cells are eluted along a size gradient
such that the
largest cells are eluted first and the smallest cells are eluted last. The
cells can also be
sorted by size using FACS. Cells of about 3 ~m to 10 ~m in diameter, or of
about 4 pm in
diameter, are isolated.
Once the muscle cells are sorted by size the muscle cells are further selected
and
then expanded in culture medium. In one embodiment the cells are cultured on a
solid
substrate that permits the adhesion of a subpopulation of cells in the
presence of a culture
medium. In one embodiment, the solid substrate is a container, such as a
tissue culture dish.
In another embodiment, the solid substrate. is in the form of beads designed
for tissue
culture. The medium can be a growth medium, or any buffer that maintains the
viability of
the cells. A variety of culture media are known and are suitable for use.
Generally, the
growth medium includes a minimal essential medium. In one embodiment, the
medium is
(Dulbecco's Modified Eagle's Medium (DMEM) and/or F12, or a combination of
DMEM
and F12 (at a ratio between about 1:1 to about 10:1).
The growth medium may be supplemented with serum. Specific, non-limiting
examples of serum are horse, calf or fetal bovine serum. The medium can have
between
about 3% by volume to about 10% by volume serum, or about 5% by volume serum.
In one embodiment, the medium contains one or more additional additives such
as
nutrients. Specific, non-limiting examples of these nutrients are shown in the
table below:
Additive Exemplary Concentration
serum About 3% to about 10%
insulin About 5 pg/ml to about 10 pg/ml
transferrin About 5 p,g/ml to about 10 wg/ml
selenium About 6 ng/ml
ethanolamine About 2 ~g/ml
EGF About 5 ng/ml to about 10 ng/ml
FGF About 5 ng/ml to about 10 ng/ml
gentamycin About 25~g/ml to about 50 ~g/ml
fungizone I About 0.2 ~g/ml to about 2.5 ~.g/ml
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-22-
The muscle stem cell growth media can also be supplemented with growth
factors.
In one embodiment, the growth medium includes basic fibroblast growth factor
(bFGF). In
one specific example, the growth medium includes between about 2 ng/ml to
about 100
ng/ml of bFGF, such as for example between about 5 ng/ml to about 50 ng/ml,
between
about 8 ng/ml to about 20 ng/ml, or between about 5 to about 10 ng/ml bFGF. In
yet
another example, the medium includes about 10 ng/ml bFGF. In another
embodiment, the
growth medium includes epidermal growth factor (EGF). In one specific example,
the
growth medium includes between about 2 ng/ml to about 100 ng/ml of EGF, such
as for
example between about 5 ng/ml to about 50 ng/ml, between about 8 ng/ml to
about 20
ng/ml, or between about 5 ng/ml to about lOng/ml EGF. In yet another example,
the
medium includes about 10 ng/ml EGF. Thus in one specific, non-limiting
example, the
growth medium is 1:1 DMEM/F12 and includes 5% fetal bovine serum, 10 ng/ml
FGF, 10
ng/ml EGF, 5 pg/ml insulin, S pg/ml transfernn, 6 ng/ml selenium, 2 pg/ml
ethanolamine.
In one specific, non-limiting example the cells are cultured in the growth
medium
for about 4 days to about 8 days. In another specific, non-limiting example,
the cells are
cultured in the growth medium for about 6 days to about 7 days.
During the period that the cells are cultured in the presence of growth
factors, the
cells cluster and increase in size. Within the clusters the cells are between
about 5-20 pm in
diameter, or between about 10-14 pm in diameter.
A method is also provided for isolating spoc cells (e.g. c-kit c-met CD34-Sca-
1-
Pax(3/7)~ cells) wherein the spoc cells are identified using specific binding
agents, such as
antibodies, for example monoclonal antibodies that recognize cell surface
markers. This
particular method of isolation of the spoc cells includes obtaining the cells
from the muscle
of a subject, as described above. In one embodiment, the cells are selected by
size (see
above) and then the spoc cells are identified using the specific binding
agents, such as
antibodies that recognize the c-met, c-kit, CD34, Sca-1 cell surface markers.
In one embodiment the c-met, Sca-1, CD34, and c-kit antibodies are
immobilized.
A particular embodiment uses magnetic column cell sorting. This method
involves a
combination of monoclonal antibodies which are covalently bound to the surface
of
magnetic beads and which are directed to cell surface markers which are absent
from the
cells being selected. For example, to isolate a spoc cell that does not
express c-met, c-kit,
CD34, or Sca-1 (c-met c-kit CD34~Sca-1-), monoclonal antibodies to c-met, c-
kit, CD34, and
Sca-1 bound to magnetic beads are used. All cells expressing either CD34, Sca-
1, c-met, or
c-kit, or any combination of these cell surface markers, will be bound by the
antibodies and
retained by the beads. Since the cells bound to the magnetic beads are
immobilized by the
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-23-
magnet, the c-met c-kit CD34~Sca-1- cells that remain in suspension can be
isolated from the
other cells. In a further embodiment, cells that are initially isolated
because they are c-kit c-
met CD34~ can be further sorted into Sca-I- and/or Sca-I+ c-kifc-met CD34-
cells.
In another embodiment, purified populations of cells are isolated via FACS.
Fluorescent-tagged antibodies against the c-met, c-kit, CD34, and Pax(3/7)
markers can be
used to distinguish c-kit c-met CD34-Pax(3/7)- cells from cells that express
any combination
of the c-met, c-kit, CD34, and Pax(3/7) markers. In a further embodiment, the
c-kit c-met
CD34-Pax(3/7)- cells can be further sorted into Sca-I- or Sca-1+cells. Thus,
cells are isolated
that are either c-kit c-met CD34-Pax(3/7)-Sca-I- or c-kit c-met CD34-Pax(3/7)-
Sca-1+.
In other embodiments a single antibody, or a combination of antibodies, can be
covalently bound to inert beads, such as sepharose beads. The beads can be
packed in a
column or maintained as a slurry. The cells expressing one or more of the cell
surface
markers are recognized by one or more of the antibodies, thus becoming bound
to the beads,
thereby identifying a subpopulation of unbound cells that does not express the
combination
of cell surface markers.
In another embodiment the antibodies are not immobilized. In a particular
embodiment the addition of the antibodies to a mixture of cells causes the
aggregation of
cells expressing the cell surface markers recognized by the antibodies. The
cells not
expressing the cell surface markers are excluded from the aggregates and can
be isolated.
Spoc cells isolated by these or other methods can be maintained in culture.
The
spot cells can further be differentiated into cardiomyocytes.
Methods of Differentiating Muscle Stem Cells
A method is disclosed herein for differentiating a spot cell (e.g. a c-kit c-
met CD34
Sca-1-Pax(3/7)- cell) into a cardiomyocyte. In a particular example, the
cardiomyocyte is a
spontaneously beating cardiomyocyte.
In one embodiment, differentiation into cardiomyocytes is induced by culturing
cells in medium similar to the growth medium, but which does not include at
least one
growth factor. Thus, a specific, non-limiting example of a differentiation
medium is a
growth medium that lacks at least one growth factor. Growth factors removed
from the
medium include, but are not limited to, bFGF or EGF, or a combination of bFGF
and EGF.
Removal of at least one growth factor causes the cells to adhere to the tissue
culture
dish and acquire characteristics of a differentiated cardiomyocyte.
Differentiation refers to
the process whereby relatively unspecialized cells, such as spot cells (e.g. c-
met c-kit CD34-
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-24-
Sca-l~Pax(3/7)- muscle-derived stem cells), acquire specialized structural
and/or functional
features characteristic of mature cells, such as cardiomyocytes.
Differentiation of spoc cells (e.g. c-met c-kit CD34~Sca-1-Pax(3/7)- cells)
into
cardiomyocytes, such as spontaneously beating cardiomyocytes, can be measured
by any
S method known to one of skill in the art. Specific, non-limiting examples are
immunohistochemical analysis to detect expression of cardiac polypeptides
(e.g. troponin-T,
L-type calcium channel, or cardiac-specific transcription factors GATA-4, or
Nkx2.5), or
assays such as ELISA assay and Western blot analysis. Differentiation of cells
can also be
measured by assaying the level of mRNA coding for cardiac polypeptides using
techniques
such as Northern blot, RNase protection and RT-PCR. In another embodiment, the
number
of spontaneously beating cells is assessed.
Calcium transients, or the flux in intracellular calcium concentrations, can
be used
as a measure of cardiomyocyte differentiation. In one embodiment calcium
imaging is used
to measure calcium transients. For example, ratiometric dyes, such as fura-2,
fluo-3, or
fluo-4 are used to measure intracelluar calcium concentration. The relative
calcium levels in
a population of cells treated with a ratiometric dye can be visualized using a
fluorescent
microscope or a confocal microscope. In other embodiments, the membrane
potential
across the cell membrane is monitored to assess calcium transients. For
example, a patch
clamp is used. In this method, an intracellular microelectrode is inserted
into the
cardiomyocyte.
In one embodiment, calcium transients can be seen before observable
contractions
of the cardiomyocytes. In other embodiments calcium transients are seen either
during, or
after, observable contractions of cardiomyocytes. In another embodiment the
cells are
cultured in the presence of conditions wherein the cells do not beat, such as
in the presence
of a calcium chelator (e.g. EDTA or EGTA) and the calcium transients are
measured.
Methods for Treatment of Cardiac Diseases or Disorders
In other embodiments, methods are provided for treating a subject suffering
from a
disease or a disorder, such as myocardial injury, or alleviating the symptoms
of such a
disorder, by administering cells isolated and cultured according to the
methods disclosed.
In one embodiment, spoc cells (e.g. c-met c-kit CD34-Sca-l~Pax(3/7)~ cells)
are
isolated as described herein and a therapeutically effective amount of spoc
cells is
administered to the subject. In another embodiment, a mixture of a
therapeutically effective
amount of c-kit c-met CD34-Pax(3/7)-Sca-1- cardiomyocyte precursor cells and a
therapeutically effective amount of c-kit c-met CD34-Pax(3/7)-Sca-1+ cells is
administered
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-25-
to the subject. In a further embodiment, spot cells are isolated and
differentiated into
cardiomyocytes, as disclosed above, and a therapeutically effective amount of
the
differentiated cells are administered to a subject, such as a human. The cells
may be
administered in any fashion, for example in a dose of, for example 0.25-1.0 x
106 cells.
Different dosages can of course be used depending on the clinical
circumstances. The cells
may be administered systemically (for example intravenously) or locally (for
example
directly into a myocardial defect under echocardiogram guidance, or by direct
application
under visualization during surgery). In another example, the cells are
administered in a gel
matrix (such as Gelfoam from Upjohn Company) which polymerizes to form a
substrate in
which the administered cells can grow.
In one embodiment the subject has a myocardial injury. The myocardial injury
may
be due to trauma that occurred as the result of an object or projectile, such
as a knife or a
bullet, having penetrated the myocardium, or as a consequence of surgery to
remove, for
example, a tumor. Myocardial injury may also result from diseases such as
cardiomyopathy, myocardial infarction, or congenital heart disease. In one
specific, non-
limiting example, a therapeutically effective amount of spot cells (e.g. c-met
c-kit CD34
Sca-1-Pax(3/7 j- cells) is administered to the subject with a myocardial
injury. In another
specific, non-limiting example, a mixture of a therapeutically effective
amount of c-kit c-
met CD34-Pax(3/7)-Sca-1- cardiomyocyte precursor cells and a therapeutically
effective
amount of c-kit c-met CD34-Pax(3/7)-Sca-1+ cells is administered to the
subject with a
myocardial injury.
In another embodiment the subject is suffering from cardiac dysfunction which
includes, for example, abnormal or improper functioning of the heart valves,
or abnormal
communication between the chambers of the heart. In one specific, non-limiting
example, a
therapeutically effective amount of spot cells (e.g. c-met c-kit CD34-Sca-1-
Pax(3/7)- cells) is
administered to the subject with a cardiac dysfunction. In another specific,
non-limiting
example, a mixture of a therapeutically effective amount of c-kit c-met CD34-
Pax(3/7)-Sca-
1- cardiomyocyte precursor cells and a therapeutically effective amount of c-
kit c-met CD34-
Pax(3/7)-Sca-1+ cells is administered to the subject with a cardiac
dysfunction.
In one embodiment the spot cells (e.g. c-met c-kit CD34-Sca-1-Pax(3/7)- cells)
or
differentiated cardiomyocytes are administered systemically by injection. In
another
embodiment, a mixture of a therapeutically effective amount of c-kit c-met
CD34~Pax(3/7)-
Sca-1- cardiomyocyte precursor cells and a therapeutically effective amount of
c-kit c-met
CD34-Pax(3/7)-Sca-1+ cells is administered systemically by injection.
Specific, non-limiting
examples of administration by injection include administration by subcutaneous
injection,
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-26-
intramuscular injection, or intravenous injection. If administration is
intravenous, an
injectible liquid suspension of spot cells can be prepared and administered by
a continuous
drip or as a bolus.
In one embodiment, the spot cells (e.g. c-met c-kit CD34-Sca-1-Pax(3/7)-
cells) or
differentiated cardiomyocytes are administered locally. In another embodiment,
a mixture
of a therapeutically effective amount of c-kit c-met CD34-Pax(3/7)'Sca-1-
cardiomyocyte
precursor cells and a therapeutically effective amount of c-kit c-met CD34-
Pax(3/7)-Sca-1+
cells is administered locally. One specific, non-limiting example of local
administration is
intra-cardiac muscle injection. For intra-cardiac injection, the spot cells
are in an injectible
liquid suspension preparation or in a biocompatible medium which is injectible
in liquid
form and becomes semi-solid at the site of damaged myocardium. A conventional
intra-
cardiac syringe or a controllable endoscopic delivery device can be used so
long as the
needle lumen or bore is of sufficient diameter (e.g. 30 gauge or larger) that
shear forces will
not damage the spot cells.
In other embodiments the spot cells (e.g. c-met c-kit CD34-Sca-l~Pax(3/7)-
cells),
differentiated cardiomyocytes, or a mixture of a therapeutically effective
amount of c-kit c-
met CD34~Pax(3/7)~Sca-1- cardiomyocyte precursor cells and a therapeutically
effective
amount of c-kit c-met CD34-Pax(3/7)-Sca-1+ cells are administered locally on a
support
medium. One specific, non-limiting example of a support medium is a sterile
mesh, or
matrix, upon which the cells are cultured. A layer of cardiomyocytes, for
example a
confluent layer of cardiomyocytes, cultured on such a matrix can be applied
locally, or
grafted at or near, a site of myocardial injury. In one embodiment the support
medium is a
biodegradable mesh. In another embodiment the support medium is not
biodegradable. The
size of the mesh, and the density of cells on it, can vary depending on the
myocardial defect
being treated.
In another embodiment the cells are encapsulated prior to administration, such
as by
co-incubation with a biocompatible matrix known in the art. A variety of
encapsulation
technologies have been developed (e.g. Lacy et al., Science 254:1782-84, 1991;
Sullivan et
al., Science 252:7180712, 1991; WO 91/10470; WO 91/10425; U.S. Patent No.
5,837,234;
U.S. Patent No. 5,011,472; U.S. Patent No. 4,892,538). During open surgical
procedures,
involving direct physical access to the heart, all of the described forms of
spot cell delivery
preparations are available options.
In one embodiment, transformed spot cell lines (e.g. c-met c-kit CD34-Sca-1-
Pax(3/7)- cells) beat and divide continuously. In specific, non-limiting
examples,
transformed spot cells, transformed differentiated cardiomyocyte cells, or a
mixture of
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-27-
transformed c-kit c-met CD34-Pax(3/7)-Sca-1- cardiomyocyte precursor cells and
transformed c-kit c-met CD34-Pax(3/7)~Sca-1+ cells are used to obtain enough
cells to
produce a "pumping patch" to repair a diseased and failing heart. In one
embodiment,
transformed spoc cells derived ex vivo from a subject are introduced into a
subject through
the circulation. In another embodiment, transformed spoc cells derived ex vivo
from a
subject are introduced into a subject directly into the heart using a guided
catheter. In
several embodiments, transformed spoc cells derived ex vivo from a subject are
used
together with endothelial cell precursors, muscle fibroblasts, or other
support cells from a
subject to produce a patch of vascularized beating cells that is placed in the
heart as an assist
device. The patch is synchronized to the rest of the heart either by capturing
the intrinsic
cardiac pacing current or by the use of a pacemaker implant that entrains the
entire heart.
The cells of the disclosure can be repeatedly administered at intervals until
a desired
therapeutic effect is achieved.
Use of Spoc Cells Produced to Screen Agents
that Affect Cardiomyocyte Differentiation or Function
In other embodiments, methods are provided for screening agents that affect
cardiomyocyte differentiation or function. According to this method, a
population of spoc
cells (e.g. c-met c-kit CD34-Sca-1-Pax(3/7)- cells) or differentiated
cardiomyocytes is
produced as described above. The population of cells is contacted with an
agent of interest,
and the effect of the agent on the cell population is then assayed. The effect
on
differentiation, survival, proliferation, or function of the cells is
assessed.
The methods described herein can be used to assess the effect of an agent on
cardiomyocyte differentiation. In order to assess the effect of a test agent
on cardiomyocyte
differentiation or function, the agent is contacted either to spoc cells (e.g.
c-met c-kit CD34
Sca-1-Pax(3/7)- cells) or CS cells. In several embodiments the spoc cells are
maintained in
medium including a growth factor between about 1 day to about 8 days, between
about 4
days to about 7 days, or about 7 days before the addition of an agent.
In another embodiment the growth factor is removed from the medium, generating
CS cells, at or before the agent is added. In several specific, non-limiting
examples CS cells
are maintained in the medium between about 1 day to about 56 days, between
about 7 days
to about 28 days, or between about 14 days to about 21 days before the
addition of an agent.
Differentiation of spoc cells (e.g. c-met c-kit CD34-Sca-1-Pax(3/7)- cells)
contacted
with an agent can be assessed by any means known to one of skill in the art.
In one
embodiment the morphology is examined, for example electron microscopy is used
to assess
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-28-
the ultrastructure of the cells. Suitable parameters for evaluation include,
but are not limited
to the evaluation of gap junctions between contacting cardiomyocytes. In other
embodiments, immunohistochemical or immunofluorescence techniques are used to
assess
differentiation. In yet another embodiment, differentiation is assessed by
analysis
expression of specific mRNA molecules expressed in cardiomyocytes. Suitable
assay
systems include, but are not limited to RT-PCR, in situ hybridization,
Northern analysis, or
RNase protection assays. In a further embodiment the levels of polypeptides
expressed in
differentiated cardiomyocytes are assayed. Specific, non-limiting examples of
polypeptide
assays of use include Western blot analysis, ELISA assay, or
immunofluorescence.
Alternatively, calcium transients are measured, as described above.
The assay can also be used to screen the effect of an agent on cardiomyocyte
function. Any method known to one of skill in the art can be utilized to
assess cardiac
function. In one embodiment the beating rate of a cardiomyocyte is assayed to
identify
agents that increase or decrease beating. One method for assessing the beating
rate is to
observe beating under a microscope. Agents that can be screened in this manner
include
inotropic drugs, such as sympathomimetic agents.
In one embodiment, cells contacted with the agent are compared with a control.
Suitable controls include spoc or CS cells not contacted with the agent, or
contacted with
vehicle alone. Standard values can also be used as a control.
In one embodiment, transformed cardiac cell lines are used to screen
therapeutic
agents, derived from combinatorial chemical libraries, in high throughput
assays. In several
embodiments, the transformed cardiac cell lines are made from skeletal muscle
of
transgenic, knockout, or knockin mouse cell lines that are produced to study
genes that are
important to cardiac function and development.
In another embodiment, the transcriptome of the spoc cells at different stages
of
differentiation or the transformed spoc cells are determined by RNA array
techniques
(cDNA arrays, gene chip oligonucleotide arrays, SAGE analysis, or subtraction
libraries). A
fingerprint consisting of subsets of the transcriptome of these different cell
populations is
used to screen (by PCR based or array analysis) candidates for analogous
precursor and
stem cells from human subjects. The selected cells can then be transformed or
expanded in
primary cell cultures.
Kits
The cells described herein are ideally suited for the preparation of a kit.
The kit can
include a carrier means, such as a box, a bag, or plastic carton. In one
embodiment the
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-29-
carrier contains one or more containers such as vials, tubes, and the like
that include a
sample of spoc cells (e.g. c-met c-kit CD34-Sca-1-Pax(3/7)- cells) and/or a
sample of c-met
c-kit CD34-Sca-1+Pax(3/7)- cells. In another embodiment, the Garner includes a
container
with an agent that affects differentiation, a buffer, or a vehicle for the
introduction of the
cells. Instructions can be provided to detail the use of the components of the
kit, such as
written instructions, video presentations, or instructions in a format that
can be opened on a
computer (e.g. a diskette or CD-ROM disk). These instructions indicate, for
example, how
to administer the cells to treat a myocardial defect or how to use the cells
to screen test
agents of interest (such as inotropic drugs).
Without further elaboration, it is believed that one skilled in the art can,
using this
description, utilize the present invention to its fullest extent. The
following examples are
illustrative only, and not limiting of the remainder of the disclosure in any
way whatsoever.
EXAMPLES
EXAMPLE 1
Method of Isolating and Expanding Cardiomyocyte Precursor Cells
from Adult Mouse Skeletal Muscle
Skeletal muscle tissue from hind legs of 6-10 week-old male C57B1/SJ6 mice was
cut into small pieces and digested with collagenase for two hours at 37
°C. The digested
tissue was cleared of cell debris and other undigested tissue fragments by
passage through a
100 pm filter and then through a 40 pm filter (Falcon). The cell suspension
was centrifuged
at low speed (1,400 rpm) to clear as much as of the small muscle fiber
fragments as
possible. The cells at this stage consisted mostly of clusters of small round
cells
approximately 4 p,m in diameter, called spoc (skeletal-based precursors of
cardiomyocytes)
cells. The cells were further fractionated using Sca-1 antibody on a Miltenyi
magnetic
column. The spoc cells eluted in the Sca-1- fraction and consisted of mostly
non-adherent
round cells, whereas the Sca-1+ fraction consisted mainly of adherent cells.
The spoc cells were plated at a density of approximately 105 cells per cmz in
regular
tissue culture dishes in complete growth medium (1:1 DMEM/F12 supplemented
with 5%
fetal bovine serum (FBS), 10 ng/ml human EGF, 10 ng/ml human bFGF (PeproTech,
Inc.),
5 pg/ml insulin, 5 pg/ml transferrin, 6 ng/ml selenium, 2 pg/ml ethanolamine
(ITS-X,
Invitrogen Corporation), 25 p,g/ml gentamicin and 2.5 pg/ml fungizone (Life
Technologies)). After a few days, the culture consisted of a floating
population of round
cells and some adherent fibroblasts. The round cells enlarged as they
underwent a few
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-30-
rounds of cell division during which time they became clusters of floating
round cells with
an increased diameter of 10-14 Vim. The cells in these clusters were GATA-4
positive and
were referred to as CS (cardiac precursors from spoc) cells.
EXAMPLE 2
Method of Differentiating Spoc Cells into Cardiomyocytes
CS cells were gently collected after seven days of growth in complete growth
medium. The cells were then plated in the same medium in the absence of EGF
and bFGF
(differentiation medium) and were maintained at 37 °C. To assess the
progression of
differentiation of the cells, the cultures were observed at various time
points using an
inverted light microscope. Beating frequency measurements of the
cardiomyocytes were
obtained by video microscopy.
Under the differentiation culture conditions the cells gradually began to
attach to the
culture dish, and elongate in shape, taking on the appearance of myoblasts.
Within a few
days of being maintained in the differentiation medium, the cells began
spontaneously
beating. Elongated uninucleate cells (60 pm in length) and round uninucleate
cells (15 p,m
in diameter) both exhibited spontaneous beating. By four days post replating
the beating
cells were more numerous. The beating cells did not undergo any more cell
divisions and
were maintained in this medium for several weeks, with the maintenance of the
spontaneous
beating phenotype. Spontaneous beating was continuous and measured at a
frequency of 1-
8 Hz. Small contractions observed in a day 14 cell (30 ~m in length) were
likely the
consequence of an immature contractile apparatus (Figure 1C). Cells kept at
room
temperature beat continuously for at least 3 hours. Cells continue to beat
even after culture
for 3 months. The isolation and differentiation of spoc cells from skeletal
muscle is
extremely reproducible and has been performed successfully more than seventy
times.
EXAMPLE 3
Immunofluorescence of Spoc Cells
Cultured cells derived from skeletal muscle were fixed in 4% paraformaldehyde
at
4°C for 10 minutes, then washed in PBS for a total of 15 minutes (3
times). Cells were
permeabilized with 0.2% Triton x-100 for 10 minutes. Blocking was performed
for 30
minutes at room temperature with either 3% BSA in PBS, 5% goat serum in PBS,
or 10%
goat serum in PBS. Incubation with primary antibody was performed at
4°C overnight.
Primary antibodies used are directed against myoD (Novocastra), Sca-1
(Cedarlane), CD34
and CD45 (PharMingen). GATA-4, Myf-5, myogenin, Pax 3/7, c-met, and cKit
antibodies
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-31-
are from Santa Cruz. RLCP antibody was generated by ResGen. Cells were then
washed
for a total of 15 minutes (5 times), in 1X PBS. Incubation with secondary
antibody was
done at room temperature for 1 hour. Afterwards, cells were washed 3 times
with PBS.
Fluorescent mounting medium with DAPI (Vector) and cover slip were then placed
over
sample. Images of cells were obtained with a laser scanning confocal
fluorescence
microscope (Leica TCS-4D DMIRBE) equipped with argon and argon-krypton laser
sources. Excitation wavelengths of 365 nm (DAPn, 488 nm (FITC), and 568 nm
(rhodamine) were used to generate fluorescence emission in blue, green, and
red,
respectively.
The non-adherent subpopulation of cells that was isolated from skeletal muscle
has
been named "spoc" cells (skeletal-based precursors of cardiomyocytes) because
of their
capacity to develop into beating cardiomyocytes. Spoc cells are CD34-, CD45-,
and c-kit ,
differentiating them from other nonadherent cells previously described as
derived from
skeletal muscle (Deasy et al., Blood Cells Mol Dis 27, 924, 2001). Spoc cells
are
distinguished from satellite cells by the following criteria:
(1) Spoc cells do not express Pax-7 (Seale et al., Cell 102, 777, 2000) or the
surface
marker c-met (Cornelison & Wold Dev Biol 191, 270, 1997);
(2) Approximately the same number of spoc cells are isolated from both young
(less
than 4-week-old) and older ( 12-16 week-old) mice, whereas satellite cells are
only
efficiently isolated from uninjured muscle of young mice (less than 4 weeks
old);
(3) Spoc cells are round, floating cells approximately 4 ~m in diameter, while
satellite cells are adherent in nature; and
(4) Spoc cells are CD34- and MyfS-, excluding them from the class of quiescent
satellite cells (Beauchamp et al., J Cell Biol 151, 1221, 2000).
The three skeletal muscle super regulatory genes MyfS, MyoD and Myogenin are
known to be present at some time in satellite cells (Cornelison & Wold Dev
Biol 191, 270,
1997). Because all three markers are negative from day 0 throughout long-term
culture,
these cells are neither satellite cells nor further developed skeletal muscle
cells.
Additionally, spoc cells do not survive when cultured under conditions that
support satellite
cell growth and differentiation into myotubes.
EXAMPLE 4
Detection of Cardiac-Specific Polypeptides by Immunofluorescence (1)
The specimens (cultured cells derived from skeletal muscle) were air-dried for
30
minutes and then fixed in 4% paraformaldehyde at 4 °C followed by a
rinse for 5 minutes
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-32-
with phosphate buffered saline (PBS). They were blocked with goat serum for 30
minutes
and then incubated overnight, at 4 °C, with either GATA-4 (mAb H-112,
Santa Cruz
Biotechnology), sarcomeric myosin (MF-20 Ab, ATTC), cardiac-specific troponin-
T (mAb
RDI-TRK4T19-lAl l, Molecular Probes, Inc.), cardiac L-type calcium channel
(mAB
AB5412-2000U1a, Chemicon Inc.), cardiac-specific transcription factor Nkx2.5
(mAb N-
19, Santa Cruz Biotechnology), or connexin 43 (mAb 71-07000, Zymed
Laboratories Inc.)
(1:200). Following the overnight incubation, the specimens were rinsed 3 times
(5 minutes
each) with PBS and blocked again with goat serum for 30 minutes. The specimens
were
then incubated at room temperature with a secondary antibody, conjugated with
either
Fluorescein Isothiocyanate (FITC), Texas Red, or Tetramethylrhodamine
Isothiocyanate
(TRITC), for 1 hour. They were again rinsed 3 times (5 minutes each) with PBS
and then
visualized with a laser confocal microscope (Leica) to detect fluorescent
signals.
The earliest time of GATA-4 expression is after 3 days in culture in growth
factor
containing medium. Within 3 days after replating the cells in factor-
containing medium
(differentiation medium), some cells begin to express sarcomeric myosin.
Cytospins of day
7 CS cells stained with monoclonal antibodies demonstrate the expression of
cardiac-
specific transcription factor GATA-4, sarcomeric myosin, and cardiac-specific
troponin-T.
Day 14 cells stained for GATA-4 and sarcomeric myosin. Overlays of images of
cells
stained with GATA-4 and sarcomeric myosin demonstrated that they were co-
localized in
the cell. At this early stage in development some cells may either be positive
for GATA-4
or sarcomeric myosin. By day 28, the majority of cells express both proteins.
By day 21
the cells are positive for cardiac L-type calcium channel, cardiac-specific
transcription
factor Nkx2.5, and connexin 43.
EXAMPLE 5
Detection of Cardiac-Specific Polypeptides by Immunotluorescence (2)
Cultured cells derived from skeletal muscle were fixed in 4% paraformaldehyde
at
4°C for 10 minutes, then washed in PBS for a total of 15 minutes (3
times). Cells were
permeabilized with 0.2% Triton x-100 for 10 minutes. Blocking was performed
for 30
minutes at room temperature with either 3% BSA in PBS, 5% goat serum in PBS,
or 10%
goat serum in PBS. Incubation with primary antibody was performed at
4°C overnight.
Primary antibodies used are directed against myoD (Novocastra), MF-20 (ATTC),
GFP
(Clontech), cardiac L-type channel (US Biologicals), Sca-1 (Cedarlane), CD34
and CD45
(PharMingen), and cardiac troponin-T (Research Diagnostics). GATA-4, Myf-5,
myogenin,
connexin 43, Nkx-2.5 Pax 3/7, c-met, and cKit antibodies are from Santa Cruz.
RLCP
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-33-
antibody was generated by ResGen. Cells were then washed for a total of 15
minutes (5
times), in 1X PBS. Incubation with secondary antibody was done at room
temperature for 1
hour. Afterwards, cells were washed 3 times with PBS. Fluorescent mounting
medium
with DAPI (Vector) and cover slip were then placed over sample. Images of
cells were
obtained with a laser scanning confocal fluorescence microscope (Leica TCS-4D
DMIRBE)
equipped with argon and argon-krypton laser sources. Excitation wavelengths of
365 nm
(DAPI), 488 nm (FITC), and 568 nm (rhodamine) were used to generate
fluorescence
emission in blue, green, and red, respectively.
During the first 7 days in factor-containing medium, spoc cells undergo
several
rounds of division, begin to express GATA-4 (cardiac-specific transcription
factor), and
become clusters of floating round "CS" cells (cardiac precursors from spoc
cells) with an
increased diameter of 10-14 Vim. These cells go on to express other cardiac
specific markers
including cardiac troponin-T, Nkx-2.5, and a cardiac specific L-type calcium
channel. Even
before they become adherent, some cells begin to beat, and by day 14 following
replating,
10% of the cells in a confluen, dish beat spontaneously. Spoc cells do not
appear to be bone
marrow cells sequestered in skeletal muscle and as they are cKit , they are
distinguished
from the cKit+bone marrow cells and side population (SP) cells that have been
used directly
or indirectly in experiments to reconstitute infarcted heart (Jackson et al.,
J Clin Invest 107,
1395, 2001; Orlic, et al., Nature 410, 701, 2001). When marrow or dissociated
total heart is
co-cultured with GFP-labeled spoc cells either directly or in permeable
membrane-separated
compartments, only the labeled spoc cells develop into beating cardiomyocytes.
Thus, bone
marrow and heart do not contain a cell population that can be isolated in this
manner and
that is phenotypically similar to spoc cells.
EXAMPLE 6
Ultrastructure of differentiated cardiomyocytes
For routine transmission electron microscopy, cultured cells derived from
skeletal
muscle were fixed in situ on Petri dishes with 1.25% glutaraldehyde in 0.1 M
cacodylate
buffer containing 1% CaCl2 at 4 °C for 2 hours. Following fixation,
cells were washed three
times in Sabatini's solution (0.1 M cacodylate buffer containing 6.8%
sucrose), and post-
fixed with 1% osmium tetroxide in cacodylate buffer for one hour. After three
washes in
Sabatini's solution, samples were dehydrated in alcohol and embedded in
Scipoxy 812
(Energy Beam Sciences, Inc. Agawarm, MA). Polymerization was carried out at 37
°C for
24 hours and then at 60 °C overnight. Ultra-thin sections were cut with
a Leica Ultracut
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-34-
UCT ultramicrotome, stained with uranyl acetate and Reynolds lead citrate, and
examined
with a JEOL 1200 CXII transmission electron microscope.
In Figure l, transmission electron micrographs show the progression of CS
cells.
At day 3 following replating, when increasing numbers of cells show rhythmic
beating,
round cells with disordered myosin filaments (Figure lA) and large central
nuclei
surrounded by copious mitochondria (Figure 1D, box and detail) exist. By day 7
elongated
cells (Figure lE) contain dense bodies (Figure lE arrowhead and Figure 1B,
lower box).
Myosin filaments of characteristic 1.6 ~,m-length (Figure 1B, top box) radiate
outward. A
day 14 cell (Figures 1C and F) with a single, central nucleus shows a
stretching out of the
dense bodies, which have begun to align with filaments coursing between,
(Figure 1C).
These structures are nearly identical to those seen in embryoid body-derived
developing
cardiomyocytes (Westfall et al., Cell Motil Cytoskeleton 36, 43,1997). By day
56, the
electron-dense structures have progressed to a well-defined organized
sarcomere (Figure
1.G) with identifiable A- and I- bands and Z-lines. The beating cells also
have one or two
large centrally located nuclei surrounded by mitochondria, distinguishing them
from skeletal
myotubes, which have many subsarcolermnal nuclei.
EXAMPLE 7
Calcium Transients as a Measure of Cardiomyocyte Differentiation
Cardiomyocytes derived from spoc cells were incubated for 30 minutes at 37
°C
with fluo-3 or fluo-4 dye at a concentration of approximately 5-10 pin in
DMEM/F-12 (dyes
dissolved in DMSO 1:1 with pluronic solution). The cells were then washed with
fresh
DMEM/F-12. The images were collected with a Zeiss LSM-510 laser scanning
confocal
system and a C-Apochromat 63x objective (1.2 N.A.). Fluo-3 and fluo-4 were
excited at
488 nm with an argon laser and the emission light was collected using an LP
505 filter. The
pinhole was adjusted to produce a 5 ~m slice to minimize the influence of
axial movements
with contraction on viewing the calcium transients. All transmitted light
images were
collected simultaneously using a transmitted light detector in conjunction
with the 488 nm
excitation light. Data depth for the images was 8-bit. The size of the images
varied from
512 x 512 pixels to 128 x 128 pixels.
Calcium transients can be observed with confocal microscopy in fluo-3- and
fluo-4-
treated cells (Figure 2). Fluorescent intensity is proportional to the amount
of calcium
binding to fluo-3 dye upon release of calcium from the sarcoplasmic reticulum.
Figure 2A
shows a graphical representation of the calcium transient in a beating CS cell-
derived
cardiomyocyte. Peak intensity and baseline are shown in Figure 2B and Figure
2C,
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-35-
respectively. In some CS cells, calcium transients can be seen by confocal
microscopy even
before observable contractions are noted, suggesting the development of
cardiomyocyte
excitation elements in advance of maturing contractile elements or restriction
of cellular
motility by the dense extracellular matrix.
EXAMPLE 8
Measurement of Action Potentials in Spoc Cell-Derived Cardiomyocytes
The calcium transients indicate the existence of action potentials (APs),
which have
been characterized with patch recordings of single spoc cell-derived
cardiomyocytes in
culture. Current clamp recordings were carried out using the tight-seal whole
cell patch
technique at room temperature in Tyrode solution containing 136 mM NaCI, 5.4
mM KCI, 1
mM MgCl2, 1.8 mM CaCl2, 0.33 mM NaH2P04, 10 mM glucose, and 10 mM HEPES
(adjusted to pH 7.4 with NaOH). The pipette solution contained 20 mM KCI, 110
mM
Postassium aspartate, 1 mM MgCl2, 10 mM HEPES, 5 mM ECTTA, 0.1 mM G'TP, and 5
mM Mg2+/ATP (adjusted to pH 7.2 with KOH). Voltages were filtered at 2 kHz (-3
dB;
four-pole, low-pass Bessel filter). The resting membrane potential upon
breaking in was -
39.8 ~ 1.6 mV (n=9), but generally improved by 10 mV or more. In some cases,
cells were
hyperpolarized slightly to action potential threshold.
A variety of cardiac APs are observed in beating and non-beating cells (Fig.
3A,
3B), which both show a resting membrane potential of approximately -60 mV with
a robust
overshoot of 50-90 mV. The form and duration of the APs match the descriptions
of adult
marine cardiomyocytes APs, which lack the plateau phase seen in cardiomyocytes
of other
species (Wang et al., Circ Res 79, 79, 1996). The beating cells differ from
skeletal muscle
in that the addition of 0.5 mM CdCl2, a non-specific Mocker of L-type Cap and
Na+
channels, abolishes the action potential as expected (Piper et al. in Isolated
Adult
Cardiomyocytes 30-65 (CRC Press, Inc., Boca Raton, FL), 1989; Sperelakis, N.
in
Physiology and Pathophysiology of the Heart 101-114 (Kluwer Academic
Publishers,
Boston, MA), 1995) while having no effect on skeletal myotubes (Fig. 3C, 3E)
(Mould and
Dulhunty P.flugers Arch 437, 197, 1999; Garcia et al., J Membr Biol 168, 141,
1999).
Likewise, both beating and non-beating cardiac cells have an intact adrenergic
pathway
(Shumaker et al., Am J Physiol 261, H1937-44, 1991; Tanaka et al., Proc R Soc
Lord B Biol
Sci 263, 241, 1996; Giles et al., J Physiol 415, 233, 1989), as shown by the
increase in AP
frequency with the addition of 25 nM isoproterenol (Fig. 3D). The expected
lack of effect
(Reinecke and Marry Cardiovasc Pathol 9, 337, 2000) is observed in the
skeletal myotubes
(Fig. 3F). Uninucleate myoblasts with spontaneous calcium transients and
action potentials
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-36-
have not been described under standard culture conditions (Cognard et al.,
Development
117, 1153, 1993) and even when they are contrived by arresting cell fusion,
they retain the
electrical activity characteristic of skeletal muscle cells, such as the lack
of response to
CdCl2 (Constantin et al., Exp Cell Res 217, 497, 1995).
EXAMPLE 9
Distinguishing Spoc Cells from Bone Marrow Cells
Spoc cells are c-kit-, distinguishing them from the c-kit+ bone marrow cells
that
have been used directly or indirectly in experiments to reconstitute infarcted
heart. Despite
this, spoc cells could be derived from circulating bone marrow cells that
become c-kit after
migration to skeletal muscle. In order to more fully evaluate this question,
whole bone
marrow was fractionated into c-kit+ and c-kit- populations. Both separate and
combined
populations were cultured under the same conditions as spoc cells. None of the
3 marrow
cell populations developed into spontaneously beating cells.
To test whether marrow cells have the potential to differentiate into
cardiomyocytes
in the presence of soluble factors released from spoc cells, equal proportions
of marrow and
spoc cells were co-cultured in a Costar transwell system, in which the two
chambers are
separated by a 0.4 ~tm permeable membrane. Although the total number of cells
increased
in each compartment, the spoc cells alone differentiated into beating cells
expressing cardiac
markers.
In order to test if cell-cell contact between bone marrow and spoc cells would
lead
bone marrow cells to differentiate into cardiomyocytes, total bone marrow was
mixed in
equal proportion with EGFP-expressing spoc cells obtained from EGFP-expressing
transgenic mice (ACTbEGFP, The Jackson Laboratory). In three separate
experiments,
under the same culture conditions, total cell number increased, but only EGFP-
expressing
cells developed into beating cells. The converse experiments showed a similar
increase in
cell number, but beating cells did not express EGFP. Taken together, these
experiments
show that bone marrow does not contain any cell population phenotypically
similar to spoc
cells isolated from skeletal muscle.
EXAMPLE 10
Examining the Ability of Spoc Cells to Reconstitute Bone Marrow
Unlike the case with hematopoietic stem cells, no colony-forming units are
generated when spoc cells are cultured in methylcellulose in the presence of
erythropoietin,
1L-3, IL-6, and SCF. To evaluate the ability of spoc cells to reconstitute
bone marrow,
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-37-
standard and competitive bone marrow transplantations with spot cells were
performed. In
four mice, 3x106 bone marrow cells and 3x104 GFP + Sca-1- spot cells were
injected into
each of the lethally irradiated mice. All four mice survived, however, only a
rare GFP+
donor-derived cell was seen in the peripheral blood or bone marrow. The marrow
of six
lethally irradiated mice, injected with either 1.5x105 Sca-1- spot cells or
2x105 spot cells
unfractionated for Sca-1, could not be rescued, and all the mice died within
two weeks.
EXAMPLE 11
Distinguishing Spoc Cells from Cells Derived from the Heart
In order to determine if spot cells can be isolated from heart, as well as
skeletal
muscle, 500 mg of heart or skeletal muscle from the same mouse were
dissociated and used
to isolate cells as described in Example 1, above. The tissue was taken from
the mouse and
cultured separately under the same conditions. Approximately 3 x 105 cells
capable of
developing into beating cells were observed by days 7-8 in the skeletal muscle-
derived cells,
while none were observed in the culture of heart-derived cells. Roughly 10% of
the cells
derived from skeletal muscle exhibited spontaneous beating. Thus, only the
spot cell
preparation from skeletal muscle differentiated into beating cells expressing
cardiac
markers. Two replicate co-culture experiments of 'ooth cell populations in
Costar transwell
systems produced an increased number of cells in both chambers, but again,
only the
skeletal muscle-derived cells developed into beating cells expressing cardiac
markers.
EXAMPLE 12
Distinguishing Spoc Cells from Mesenchymal Stem Cells
To determine if spot cells can be distinguished from mesenchymal stem cells
(MSC), MSC were compared to spot cells in culture. The MSC (Clonetics
Corporation)
were cultured in parallel with spot cells generated from skeletal muscle as
described in the
methods above. The MSC adhered to the plate almost immediately upon plating,
remained
adherent throughout 12 days of observation, and did not show any sign of
beating. In
contrast, the cardiac progenitor cells from skeletal muscle were smaller in
size, remained
nonadherent while they developed into floating clusters of spot cells, and
they progressed to
beating cardiac myocytes expressing cardiac markers. Spot cells did not form
in the MSC
cultures. Thus, spot cells are not MSC.
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-38-
EXAMPLE 13
In Vivo Differentiation of Spoc Cells
In order to determine if spoc cells engraft within a myocardial infarct and
differentiate into mature cardiomyocytes, 1x105 EGFP+ spoc cells were injected
into the
peripheral circulation in acute myocardial infarct (MI) models. After 14
weeks, many
donor-derived EGFP+ cells had engrafted. Of donor cells that had migrated to
the infarct,
8% (63/782) had developed into cardiomyocytes.
To evaluate for similar effect in an older infarct, the same number of GATA-4-
negative spoc cells was injected via tail vein into 2 mice (8 and 14 weeks
status-post MI).
Two weeks following injection, the heart of the 8-week-old infarct model shows
colocalization of EGFP and GATA-4 in 3% (4/136) of donor cells that migrated
to the
peripheral region of the infarct. Five weeks following injection into the 14-
week-old infarct
model, an increased number of EGFP+/RLCP+ cells (7/102 donor-derived cells) in
the
infarct region are evident. Since spoc cells are not GATA-4 or RLCP positive
these
findings suggest that spoc cells either home to or are filtered out in an area
of cardiac
damage where they begin to differentiate into cardiomyocytes, as observed in
vitro. Spoc
cells that were partially differentiated by culturing for 7 days were injected
into the hearts .
and tail veins of 3 mice with acute infarcts. No labeled cells were identified
in the hearts at
7 days and later, compared to 2 control mice injected with saline at the time
of infarct. This
suggests that the undifferentiated cells more easily home to or are
preferentially filtered out
in the heart.
Further fractionation of spoc cells by sorting for the Sca-1 marker (surface
antigen
found on hematopoietic stem cells) demonstrates that the overwhelming majority
of beating
cells develop from the Sca-1- pool. Approximately 90% of the spoc cells are
Sca-1+ cells
that are rapidly adherent and do not develop into beating cells. With the Sca-
1+ population
removed, the remaining 10% Sca-1-population undergo 2-3 additional divisions
as
undifferentiated cells before beginning to differentiate. Some of these cells
begin to beat
while still floating. When a Sca-1-population that has reached the stage of CS
cells is
replated onto an adherent monolayer of Sca-1+ cells, the Sca-1-cells adhere to
the monolayer
within 24 hours, days before they would normally adhere. Within 3 days, they
stretch out
beyond the extent that they would otherwise and an increase in the proportion
of beating
cells is observed.
In order to determine if Sca-1- spoc cells engraft within a myocardial infarct
and
differentiate into mature cardiomyocytes, anterior myocardial infarct (Mn
models in
C57B1/6J mice were created by ligation of the left coronary artery. When 1x105
Sca-1-
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-39-
EGFP+ donor cells were injected via tail vein immediately following
infarction, a low level
of engraftment occurred, with only an occasional donor-derived cardiomyocyte
found at the
periphery of the infarct zone. No labeled cells, differentiated or
undifferentiated, were
observed in the normal portion of the infarcted heart. To overcome the low
level of
engraftment of the Sca-1- cells, a mixture of the Sca-1+ and Sca-1- cells, in
different
proportions, is provided to the mouse model.
EXAMPLE 14
Method of Producing Transformed Cell Lines that Continue to Beat and Divide
Transformed spoc cell lines that continue to beat and divide are generated.
Spoc
cells are transfected with plasmid expression vector harboring SV40 large T
antigen or
polyoma large T antigen with commercially available reagents. The cells are
cultured in
Teflon vessels and the growing population of cells is isolated and cloned.
Single
transformed cells are expanded to produce a clonal population. These cell
lines are used to
obtain enough cells to produce a "pumping patch" to repair a diseased and
failing heart.
Transformed cells derived ex vdvo from a subject are introduced into a subject
either through
the circulation or directly into the heart using a guided catheter.
Transformed cells derived
ex vivo from a subject are also used together with endothelial cell
precursors, muscle
fibroblasts and other support cells from a subject to produce a patch of
vascularized beating
cells that is placed in the heart as an assist device. The patch is
synchronized to the rest of
the heart either by capturing the intrinsic cardiac pacing current or by the
use of a
pacemaker implant that entrains the entire heart.
EXAMPLE 15
Method of Screening for Agents that
Affect Cardiomyocyte Differentiation or Function
A large variety of transformed cardiac cell lines are made from skeletal
muscle of
transgenic, knockout, or knockin mouse cell lines that were produced to study
genes that are
important to cardiac function and development. These cell lines are used to
screen
therapeutic agents, derived from combinatorial chemical libraries, in high
throughput
assays. In one embodiment, a clonal population of transformed cells can be
treated with
agents that affect calcium channels and other channels. Cells can be screened
by various
methods such as immunofluorescence or electrical activity to screen for
agonists and
antagonists that affect cardiomyocyte function. Examples of knockout mice that
may be of
interest include but are not limited to connexin-43 knockout and p53 knockout
mice.
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-40-
EXAMPLE 16
Distinguishing Spoc Cells from Satellite Cells
Spoc cells and satellite cells are air-dried on glass slides for 30 minutes
and then
fixed in 4% paraformaldehyde at 4 °C followed by a rinse for 5 minutes
with PBS. The
cells are blocked with goat serum for 30 minutes and then incubated overnight,
at 4 °C, with
rabbit anti-met (1:200, Santa Cruz Biotechnology). Following the overnight
incubation, the
slides are rinsed 3 times (S minutes each) with PBS and blocked again with
goat serum for
30 minutes. The cells are then incubated at room temperature with a secondary
antibody,
conjugated with Fluorescein Isothiocyanate (FTTC) for 1 hour. They are again
rinsed 3
times (5 minutes each) with PBS and then visualized with a laser confocal
microscope
(Leica) to detect fluorescent signals. Of the two cell types examined, only
the satellite cells
are positively stained with c-met indicating that satellite cells express c-
met on their cell
surface, whereas spoc cells do not.
EXAMPLE 17
Method of Isolating Cardiomyocyte Precursor Cells
from Adult Human Skeletal Muscle
Skeletal muscle tissue is surgically obtained from the deltoid muscle of an
adult
human, is cut into small pieces and is digested with collagenase for two hours
at 37 °C. The
digested tissue is cleared of cell debris and other undigested tissue
fragments by passage
through a 100 pm filter and then through a 40 pm filter. The cell suspension
is centrifuged
at low speed to clear as much as of the small muscle fiber fragments as
possible. The cells
at this stage consist mostly of clusters of small round cells approximately 4
pm in diameter
which are the human spoc cells. These cells do not express the satellite cell
surface marker
c-met.
The spoc cells are plated at a density of approximately 105 cells per cm2 in
regular
tissue culture dishes in complete growth medium (1:1 DMEM/F12 supplemented
with 5%
fetal bovine serum (FBS), 10 ng/ml human EGF, 10 ng/ml human bFGF (PeproTech,
Inc.),
5 ~g/ml insulin, 5 ~,g/ml transferrin, 6 ng/ml selenium, 2 ~,g/ml ethanolamine
(ITS-X,
Invitrogen Corporation), 25 p,g/ml gentamicin and 2.5 ~g/ml fungizone (Life
Technologies)). After a few days, the culture consists of a floating
population of round cells
and some adherent fibroblasts. The round cells enlarge as they undergo a few
rounds of cell
division during which time they become clusters of floating round cells with
an increased
CA 02464088 2004-04-20
WO 03/035838 PCT/US02/33860
-41-
diameter of 10-14 Vim. The cells in these clusters were referred to as CS
(cardiac precursors
from spoc) cells.
In view of the many possible embodiments to which the principles of our
disclosure
may be applied, it should be recognized that the illustrated embodiments are
only examples
of the disclosure and should not be taken as a limitation on the scope of the
disclosure.
Rather, the scope of the invention is defined by the following claims. We
therefore claim as
our invention all that comes within the scope and spirit of these claims.
